Transgene Overview

  • Founded
  • 1979
Founded
  • Status
  • Public
  • Employees
  • 176
Employees
  • Stock Symbol
  • TNG
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $2.79
  • (As of Friday Closing)

Transgene General Information

Description

Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States. Its subsidiary represents the company before various bodies, regulatory authorities and clinical sites for clinical trials it conducts in the US.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 400 Boulevard Gonthier d'Andernach
  • Parc d'Innovation
  • 67405 Illkirch-Graffenstaden
  • France
+33 03 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Transgene Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.79 $2.78 $1.48 - $3.85 $234M 83.8M 71.5K -$0.38

Transgene Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 245,182 150,712 162,835 201,746
Revenue 2,488 3,398 7,447 1,575
EBITDA (40,640) (25,219) (27,711) 13,107
Net Income (31,968) (19,642) (21,050) 9,475
Total Assets 127,241 105,104 129,354 124,282
Total Debt 5,394 6,498 18,665 44,589
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Transgene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Transgene‘s full profile, request access.

Request a free trial

Transgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted ther
Biotechnology
Illkirch-Graffenstaden, France
176 As of 2020
00000
000000000 00000

000-000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000 000000000
Vienna, VA
00 As of 0000
000.00
000000000 000.00

000000 0

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
0000 000000000
Marseille, France
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Transgene Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CEL-SCI Corporate Backed or Acquired Vienna, VA 00 000.00 000000000 000.00
000000 000000 Formerly VC-backed Marseille, France 000 00000 000000000 00000
000000 Formerly VC-backed Loos, France 000 00000 000000000. 0 00000
000000 00000000000 Venture Capital-Backed Illkirch, France 00 0000 000000000 0000
0000000 0000000000 Formerly VC-backed Newark, CA 00 00000 00000000 00000
You’re viewing 5 of 42 competitors. Get the full list »

Transgene Patents

Transgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3842065-A1 Process for designing a recombinant poxvirus for a therapeutic vaccine Pending 23-Dec-2019 00000000000
CA-3124773-A1 M2-defective poxvirus Pending 28-Dec-2018 0000000000
AU-2019412516-A1 M2-defective poxvirus Pending 28-Dec-2018 0000000000
US-20190330655-A1 Oncolytic viruses and therapeutic molecules Pending 28-Dec-2016 000000000
CA-3045228-A1 Oncolytic viruses and therapeutic molecules Pending 28-Dec-2016 C12N15/86

Transgene Executive Team (7)

Name Title Board Seat Contact Info
Eric Quéméneur Ph.D Executive Vice President & Chief Scientific Officer
Hedi Ben Brahim Chief Executive Officer & Chairman
Jean-Philippe Del Vice President & Chief Financial Officer
Antoine Béret Independent Director
Thibaut Du Fayet Vice President, Corporate Development
You’re viewing 5 of 7 executive team members. Get the full list »

Transgene Board Members (10)

Name Representing Role Since
00000 0é00000 Self Board Member 000 0000
000000 000000 Self Independent Director & Chairman, Compensation Committee 000 0000
0000 000 000000 Transgene Chief Executive Officer & Chairman 000 0000
0000-000 0é0000000 Transgene Director 000 0000
0000-000000 0000000 00 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Transgene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transgene Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 0000000000 01-Jan-2011 00000 0000000 Other Commercial Services
Transgene Tasly (Tianjin) BioPharmaceutical 01-Jan-2010 Joint Venture Pharmaceuticals
To view Transgene’s complete investments history, request access »

Transgene Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 0000000000 01-Jan-2011 00000 0000000 Completed
  • 2 buyers
Transgene Tasly (Tianjin) BioPharmaceutical 01-Jan-2010 Joint Venture Completed
  • 2 buyers
To view Transgene’s complete exits history, request access »